Cooperative Agreement UG3DA061709
Award Date
5/15/25
Completion Date
4/30/27
Dollars Obligated
$3.3M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Oregon, USA
Similar Awards
This $2,916,991 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a Phase 1B clinical trial of Myosin Therapeutics' novel therapeutic agent MT-110 for reducing methamphetamine use disorder (MUD). The trial will recruit up to 44 participants to test 5 dose levels of MT-110 and assess its safety, tolerability, pharmacokinetics, and potential effects on methamphetamine craving. This award will fund the...
This $634,048 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a human laboratory study to evaluate the effectiveness of the drug troriluzole as a treatment for methamphetamine use disorder (MUD), both alone and in cases of co-occurring MUD and opioid use disorder. The study will enroll 40 non-treatment seeking participants and assess the reinforcing effects of intravenous methamphetamine after...
The National Institute on Drug Abuse (NIDA) awarded Emory University a $1,481,760 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to study the impact of methamphetamine use on immune dysfunction and HIV reservoir activation in people living with HIV on antiretroviral therapy (ART). The key objectives are to determine how methamphetamine induces inflammasome activation, metabolic changes, and epigenetic modifications that promote immune dysfunction in T cells and...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a treatment for opioid use disorder (OUD). The award supports screening of next-generation compounds targeting the metabolic enzyme ACSS2, which has been shown to play a key role in the encoding of drug-related memories. This research aims to identify a potent ACSS2 inhibitor that...
The National Institute on Drug Abuse (NIDA) awarded a $2,402,305 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Cari Health, Inc. (Doing Business As: Clinical Addiction Recovery Institute) to develop and commercialize a new point-of-care technology to enable individualized methadone dosing for opioid use disorder (OUD) treatment. The project aims to create a device that can quickly evaluate a patient's methadone metabolism rate using a small blood...
The National Institute on Drug Abuse (NIDA) awarded a $19,302,777 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a novel medication for the treatment of opioid use disorder (OUD). The project aims to advance late-stage chemistry, manufacturing, and controls (CMC), conduct registration-enabling non-clinical studies, establish quality systems, and engage with the FDA to expedite NRS-033 into...
This $399,483 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for treating substance use disorders (SUDs). The key objectives are to: 1) use DEL screening to identify compounds that target the opioid receptor delta (OPRD1) and dopamine receptor D3 (DRD3) to...
This $11,811,988 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is supporting the development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing opioid relapse and overdose. The key products and services to be delivered include: Submitting an Investigational New Drug (IND) application for MCAM to prevent opioid relapse Completing Phase 1 and Phase 1b clinical trials with...
The National Institute on Drug Abuse (NIDA) awarded a $2,983,510 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Leland Stanford Junior University. The funding supports a two-phase study to assess the effectiveness of deep transcranial magnetic stimulation (dTMS) in modulating neural circuits associated with methamphetamine use disorder. The initial UG3 phase will enroll 30 participants to determine if the dTMS protocol can effectively engage the...
This $804,728 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to investigate the role of the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis in methamphetamine-induced promotion of HIV-1 persistence and brain injury, despite combination antiretroviral therapy (cART). The key research objectives are to: 1) Determine how methamphetamine engages the CYSLT-CYSLTR1...